-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects Enrolled into Cohort 1, and the Data Safety Monitoring Board Recommended Continuation of Subject Enrollment for the Phase 1b/2a Clinical Treatment Study- -Following the Positive Data Safety Monitoring Board Recommendation, Enrollment of Cohort 2 is Expected to ...

Benitec Biopharma Limited (BNTC) closed the last trading session at $15.49, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.71 indicates a 66% upside potential.The average comprises seven short-term price targets ranging from a low of $17 to a high of $35, with a standard deviation of $6.70. While the lowest estimate indicates an increase of 9.8% from the current ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Benitec Biopharma Limited (BNTC) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Benitec Biopharma Limited is a member of our Medical group, which includes 999 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 1 ...

Group 1 - The core viewpoint is that Benitec Biopharma Limited (BNTC) has significant upside potential, with a mean price target of $25.71 indicating an 83.9% increase from its current price of $13.98 [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $6.70, suggesting variability in analyst predictions; the lowest estimate is $17 (21.6% increase), while the highest is $35 (150.4% increase) [2] - Analysts show strong agreement on BNTC's ability to report better earnings than previously predicted, which supports the expectation of stock upside [4][11] Group 2 - The Zacks Consensus Estimate for BNTC has increased by 15.6% due to three upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]

Company Overview - Benitec Biopharma Limited (BNTC) is a notable stock within the Medical sector, currently ranked 5 in the Zacks Sector Rank, which evaluates 16 different groups based on the average Zacks Rank of individual stocks [2] - BNTC has a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimate revisions and improving earnings prospects [3] Performance Metrics - Over the past 90 days, the Zacks Consensus Estimate for BNTC's full-year earnings has increased by 61.8%, reflecting improved analyst sentiment and a more positive earnings outlook [4] - Year-to-date, BNTC has returned 7.7%, significantly outperforming the average return of -5.6% for Medical companies as a whole [4] - In the Medical - Biomedical and Genetics industry, which includes 506 stocks, BNTC is performing better than the average loss of 6.5% this year, currently ranked 77 in the Zacks Industry Rank [6] Comparative Analysis - Another outperforming stock in the Medical sector is Concentra Group (CON), which has returned 14.9% year-to-date and has a Zacks Rank of 2 (Buy) [5] - Concentra Group belongs to the Medical Services industry, which has seen a year-to-date decline of -2.4% and consists of 58 stocks currently ranked 51 [6] Future Outlook - Investors interested in Medical stocks should monitor Benitec Biopharma Limited and Concentra Group for potential continued strong performance [7]

Financial Performance - Total expenses for Q3 2025 were $10.2 million, up from $4.1 million in Q3 2024, representing a 148.8% increase[4] - The net loss attributable to shareholders for Q3 2025 was $9.4 million, or $0.24 per share, compared to a net loss of $4.3 million, or $0.23 per share in Q3 2024[5] - The company reported a total comprehensive loss of $9.4 million for Q3 2025, compared to a comprehensive loss of $4.2 million in Q3 2024[9] - Total operating expenses for the nine months ended March 31, 2025, were $24.6 million, compared to $16.9 million for the same period in 2024, indicating a 45.5% increase[9] Research and Development - Research and development expenses for the quarter were $6.0 million, compared to $2.6 million in the same quarter last year, marking a 130.8% increase[4] - The company is focused on the continued development of BB-301 for the treatment of dysphagia in OPMD patients[3] - The company plans to enroll additional subjects at a higher dose of BB-301 later this year, following the successful treatment of the sixth subject in Cohort 1[3] Assets and Cash Position - As of March 31, 2025, the company had $103.6 million in cash and cash equivalents, an increase from $50.9 million as of June 30, 2024[7] - The total assets as of March 31, 2025, were $105.2 million, compared to $52.2 million as of June 30, 2024, reflecting a 101.5% increase[7] Earnings Per Share - The basic earnings per share calculation has been revised to include pre-funded warrants in the weighted number of shares outstanding for the current and comparative periods[5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39267 BENITEC BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 84-462-0206 (State or other jurisdicti ...

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in stock prices for short-term investing, highlighting that while price movements can be profitable, they can also reverse quickly, leading to potential losses [1][2]. Group 1: Stock Performance - Benitec Biopharma Limited (BNTC) has shown a solid price increase of 43.2% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 22.2% in the last four weeks, suggesting that the upward trend is still intact [5]. - BNTC is currently trading at 83.4% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. Group 3: Investment Strategy - The article suggests using the "Recent Price Strength" screen to identify stocks like BNTC that are on an upward trend supported by strong fundamentals [3][8]. - It also mentions that there are over 45 Zacks Premium Screens available for investors to find winning stock picks based on their personal investing styles [8].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Benitec Biopharma Limited (BNTC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Benitec Biopharma Limited is a member of the Medical sector. This group includes 1001 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average ...

Core Viewpoint - Benitec Biopharma Limited (BNTC) shows significant upside potential with a mean price target of $25.71, indicating an 85% increase from the current price of $13.90 [1] Price Targets - The average of seven short-term price targets ranges from a low of $17 to a high of $35, with a standard deviation of $6.70, suggesting variability in analyst estimates [2] - The lowest estimate indicates a 22.3% increase, while the highest suggests a 151.8% upside [2] Analyst Consensus - Strong agreement among analysts regarding BNTC's ability to report better earnings than previously predicted supports the potential for stock upside [4] - The Zacks Consensus Estimate for the current year has increased by 0.7% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank - BNTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Earnings Estimate Revisions - Analysts' optimism regarding BNTC's earnings prospects, reflected in the upward revisions of EPS estimates, correlates strongly with near-term stock price movements [11]